Levetiracetam Solution
Product Images NDC 0904-7420

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0904-7420). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle-label (Bottle Label)

Bottle-label (Bottle Label)
Label for Levetiracetam Oral Solution, USP 100 mg/mL by Major Pharmaceuticals. The label is for a 16 fl oz (473 mL) prescription oral solution, includes storage instructions, warnings to keep out of reach of children, and pharmacist dispensing guidance. The product is manufactured by MSN Pharmaceuticals Inc. and distributed by Major Pharmaceuticals.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A bar graph comparing the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The y-axis represents the percentage of patients from 0% to 45%.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A bar chart showing percentages of patients in three groups: placebo (6.3%), levetiracetam 1000 mg/day (20.8%), and levetiracetam 2000 mg/day (35.2%). The y-axis represents the percentage of patients from 0% to 45%, and the x-axis categorizes the groups. Asterisks are present on the levetiracetam group bars.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A bar chart comparing the percentage of patients for placebo versus levetiracetam 3000 mg/day groups. The placebo group (N=104) shows 14.4% of patients, while the levetiracetam group (N=180) shows 39.4% of patients, as indicated above the bars. The y-axis represents the percentage of patients from 0% to 45%. An asterisk marks the bar for the levetiracetam group.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
Bar chart comparing the percentage of patients between a placebo group (n=97) and a levetiracetam group (n=101). The y-axis shows the percentage of patients, with placebo at 19.6% and levetiracetam at 44.6%. An asterisk is present on the levetiracetam bar indicating statistical significance.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A bar chart comparing the percentage of patients in two groups: Placebo (N=51) and Levetiracetam (N=58). The placebo group shows 19.6% of patients, while the levetiracetam group shows 43.1%, illustrating a higher percentage in the levetiracetam group. The y-axis represents the percentage of patients ranging from 0% to 45%.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A bar graph comparing the percentage of patients between two groups: placebo (N=84) and levetiracetam (N=79). The y-axis represents the percentage of patients, ranging from 0% to 100%. The placebo group shows 45.2% while the levetiracetam group shows 72.2%, with an asterisk above the levetiracetam bar indicating statistical significance.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of levetiracetam, the active ingredient in this oral solution drug product. The diagram shows the molecular arrangement and bonds of levetiracetam as presented in the product's labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.